Machine signal
Active cluster sell — 3 distinct insiders, $12.2M, window ends Jul 27, 2026.
Figures computed from official regulatory filings — .
Analysttarget 52.15 USD (+113%) · consensus 4.67/5 · 13 buy · 2 hold · 0 sell
Ownershipinsiders 1.25% · institutions 107.87% · short 38.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Beam Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
249 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Cavanagh Bethany J | Sell | $4.6K | SEC |
| Ciaramella Giuseppe | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simon Amy | Sell | $429K | SEC |
| Simon Amy | Sell | $13K | SEC |
| Evans John M. | Sell | $791.5K | SEC |
| Evans John M. | Sell | $471.5K | SEC |
| Evans John M. | Sell | $66.2K | SEC |
| Evans John M. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Evans John M. | Exercise | $6.5K | SEC |
| Evans John M. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Evans John M. | Exercise | $12.5K | SEC |
| Evans John M. | Sell | $415.8K | SEC |
| Evans John M. | Exercise | $25.8K | Unusual size | SEC |
| Evans John M. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FMR LLCtrack record | Sell | $1.2M | Unusual size | SEC |
| FMR LLCtrack record | Sell | $8.9M | Unusual size | SEC |
| Ciaramella Giuseppe | Exercise | $4.4K | SEC |
| Ciaramella Giuseppe | Exercise | $29.9K | SEC |
| Ciaramella Giuseppe | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ciaramella Giuseppe | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fishman Mark | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Walsh Kathleen E | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MARAGANORE JOHNtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shaw Christi | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Guindo Chirfi | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |